Blog

Immunotherapy Making Headway in SCLC and Mesothelioma – OncLive


OncLive

Immunotherapy Making Headway in SCLC and Mesothelioma
OncLive
Immune-based therapies continue to show promising signals for patients with small cell lung cancer (SCLC) and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit, according to Justin F. Gainor, MD. The

2018-03-10 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.